Lacey John III 4

What Happened

• John Lacey III, a director of Provectus Biopharmaceuticals, was granted 48,917 shares of Series D‑1 Convertible Preferred Stock on 2026-06-30. The award was recorded at $0.00 (no cash paid). Each preferred share converts into 10 shares of common stock, making the equivalent up to 489,170 common shares if converted.
• This transaction is an award/grant (code A) of a derivative security (convertible preferred), not an open-market purchase or sale. Grants are typically compensation-related and do not necessarily signal an immediate bullish or bearish view by the insider.

Key Details

• Transaction date and filing: 2026-06-30 (Form 4 accession 0001493152-26-031403).
• Instrument and price: 48,917 shares of Series D‑1 Convertible Preferred Stock at $0.00 (derivative award).
• Conversion terms (footnotes): each Series D‑1 preferred converts into 10 common shares; automatic conversion into common stock on December 31, 2028 unless earlier conversion occurs.
• Post-transaction common-share ownership: not specified in the supplied filing excerpt.
• Timeliness: filing and transaction date are the same (no late filing flag provided).

Context

• Because this is a grant of convertible preferred stock, the insider did not buy common shares outright; value depends on future conversion and market price of the common stock. Automatic conversion in 2028 means the common-share impact may occur later.
• For retail investors: such awards are common for executives/directors as compensation. They are informative about compensation structure but are not the same as an insider purchasing common stock on the open market.